By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: KFSH Highlights the Strategic Value of Tertiary Care AI Datasets in Advancing Precision Medicine and Clinical Innovation
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > KFSH Highlights the Strategic Value of Tertiary Care AI Datasets in Advancing Precision Medicine and Clinical Innovation
KFSH Highlights the Strategic Value of Tertiary Care AI Datasets in Advancing Precision Medicine and Clinical Innovation
Health

KFSH Highlights the Strategic Value of Tertiary Care AI Datasets in Advancing Precision Medicine and Clinical Innovation

GlobeNews Wire
Last updated: 12/06/2026 9:38 PM
GlobeNews Wire
Published: 12/06/2026
Share
SHARE

RIYADH, Saudi Arabia, June 12, 2026 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH) will use its participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, to highlight the strategic value of tertiary care datasets as a foundation for advancing artificial intelligence, precision medicine, and clinical innovation in highly specialized healthcare.

As a tertiary and quaternary care provider managing complex cases across oncology, organ transplantation, cardiovascular diseases, neurosciences, and genetic diseases, KFSH generates high-value clinical, genomic, imaging, and operational data that can support more accurate prediction, diagnosis, treatment planning, and research translation.

This data-driven model is particularly evident in genomic medicine. KFSH’s integrated genomic medicine program nearly doubled genomic testing between 2022 and 2024, rising from around 22,000 tests to more than 44,000. During the same period, the hospital completed more than 5,000 precision oncology analyses and activated pharmacogenomic alerts that altered treatment in 70% of documented cases.

KFSH has also strengthened the global value of population-specific datasets. The hospital has submitted nearly 8,000 variants to ClinVar and documented close to 3,000 variants specific to Arab populations, 34% of which are not represented in the Genome Aggregation Database. These contributions improve the representation of underrepresented populations and support more precise interpretation of genetic findings.

The hospital’s Genomics Medicine Centre further supports this model through advanced computational analysis, AI-powered tools, high-performance data systems, and multi-omics technologies that connect genomic and clinical information to rare disease diagnosis, cancer genomics, transplant medicine, and personalized treatment guidance.

At the event, KFSH will bring this perspective to global discussions on responsible AI, applied datasets, provider transformation, and scalable digital health models.

King Faisal Specialist Hospital has been ranked first in the Middle East and North Africa and 12th globally among the world’s top 250 Academic Medical Centers for 2026 and recognized as the most valuable healthcare brand in the Kingdom and the Middle East according to Brand Finance 2026. It has also been listed by Newsweek among the World’s Best Hospitals 2026, the World’s Best Smart Hospitals 2026, and the World’s Best Specialized Hospitals 2026.

For more information:

mediacoverage@kfshrc.edu.sa 

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
argenx to Present at TD Cowen 46th Annual Healthcare Conference
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Sinopec Launches China’s First Floating Offshore PV Project, Advancing Green Energy Innovation
News

Sinopec Launches China’s First Floating Offshore PV Project, Advancing Green Energy Innovation

04/07/2025
ASICS signs official supplier agreement with the Asian Paralympic Committee
First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear
WEMADE Launches Global MMORPG ‘Legend of YMIR’
TestMu AI Adds Samsung Galaxy S26 Series to Virtual and Real Device Cloud Ahead of Public Release
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?